LON:TILS

Tiziana Life Sciences Share Forecast, Price & News

Add

Today's Range: N/A
50-Day Range: 58.50
▼
58.50
52-Week Range: N/A

Volume: 297,127 shs
Average Volume: 522,223 shs
Market Capitalization: £113.85 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Receive TILS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tiziana Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

TILS Stock Forecast (MarketRank)

Overall MarketRank^™

0.72 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Tiziana Life Sciences.

3.6 Community Rank

Outperform Votes
Tiziana Life Sciences has received 120 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Tiziana Life Sciences has received 101 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Tiziana Life Sciences has received 54.30% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Tiziana Life Sciences and other stocks. Vote “Outperform” if you believe TILS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TILS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Tiziana Life Sciences does not currently pay a dividend.
Dividend Growth
Tiziana Life Sciences does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Tiziana Life Sciences insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Tiziana Life Sciences is -3.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Tiziana Life Sciences is -3.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Tiziana Life Sciences (LON:TILS)

Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. Its product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. The company also develops anti-IL6R (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat COVID-19 patients with severe respiratory symptoms. It has a collaboration agreement with FHI Clinical Inc. to conduct a phase 2 clinical trial for treating hospitalized severe COVID-19 patients with intranasal foralumab, a human anti-CD3 monoclonal antibody. The company was incorporated in 1998 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.

June 17, 2022 | finance.yahoo.com

Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice

June 11, 2022 | americanbankingnews.com

Tiziana Life Sciences (LON:TILS) Shares Pass Above 50-Day Moving Average of $58.50

June 9, 2022 | fool.co.uk

Tiziana Life Sciences

June 7, 2022 | investing.com

Advan Co Ltd (7463)

June 3, 2022 | americanbankingnews.com

Tiziana Life Sciences (LON:TILS) Share Price Passes Below Two Hundred Day Moving Average of $58.33

March 24, 2022 | proactiveinvestors.com

Tiziana Life Sciences: Multiple Sclerosis single study

March 24, 2022 | proactiveinvestors.com

Tiziana Life Sciences: Method of therapy delivery gives firm 'a novel market position'

January 28, 2022 | proactiveinvestors.com.au

2022 update: US listing and fresh data emerging

January 26, 2022 | lse.co.uk

MaxCyte expects improved full-year revenue on organic growth

October 28, 2021 | lse.co.uk

Tiziana Life Sciences Plc Share Chat

October 19, 2021 | finanznachrichten.de

Tiziana Life Sciences Plc: Tiziana Life Sciences plc: Court Sanctions the Scheme of Arrangement and approves Reduction of Capital

October 19, 2021 | finance.yahoo.com

Tiziana Life Sciences plc: Court Sanctions the Scheme of Arrangement and approves Reduction of Capital

September 24, 2021 | finance.yahoo.com

Tiziana Life Sciences plc - Interim Results for the Six Months Ended 30 June 2021

See More Headlines

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:TILS
Previous Symbol: LON:ADI
CUSIP: N/A
CIK: N/A
Web: www.tizianalifesciences.com
Phone: +44-20-74952379
Fax: N/A
Employees: 11
Year Founded: N/A

Company Calendar

Last Earnings: 9/30/2020
Today: 6/26/2022

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 2.36
Current Ratio: 6.54
Quick Ratio: 6.41

Sales & Book Value

Annual Sales: £-3.60 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 2.28
Book Value: GBX 23.50 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 194,612,000
Free Float: N/A
Market Cap: £113.85 million
Optionable: Not Optionable
Beta: N/A

Tiziana Life Sciences Frequently Asked Questions

How were Tiziana Life Sciences' earnings last quarter?: Tiziana Life Sciences PLC (LON:TILS) posted its quarterly earnings results on Wednesday, September, 30th. The biotechnology company reported ($2.60) earnings per share for the quarter, topping the consensus estimate of ($4.00) by $1.40.
View Tiziana Life Sciences' earnings history.
Who are Tiziana Life Sciences' key executives?: Tiziana Life Sciences' management team includes the following people:
Mr. Gabriele Marco Antonio Cerrone M.B.A., MBA, Founder & Exec. Chairman (Age 49, Pay $13.76M)
Dr. Kunwar Shailubhai, CEO, Chief Scientific Officer & Exec. Director (Age 63, Pay $810k)
Dr. Andrea Brancale, Scientific Founder
Mr. Richard Clarkson Ph.D., Scientific Founder
Mr. Andrew Westwell Ph.D., Scientific Founder
Ms. Keeren Shah, Fin. Director (Age 44)
Dr. Thomas H. Adams, Head of Drug Devel. & Exec. Director (Age 78)
Dr. Neil Graham M.P.H., MBBS, M.D., MPH, Chief Medical Officer (Age 62)
Dr. Napoleone Ferrara, Chairman of Scientific Advisory Board (Age 63)
Prof. Roberto Pellicciari, Consultant
Who are some of Tiziana Life Sciences' key competitors?: Some companies that are related to Tiziana Life Sciences include Pfenex (PFNX), Dyne Therapeutics (DYN), ProMetic Life Sciences (PLI), Horizon Discovery Group plc (HZD.L) (HZD), Precigen (PGEN), Theratechnologies (TH), Inventiva (IVA), VIVO Cannabis (ABCN), Emblem (EMC), Verona Pharma plc (VRP.L) (VRP), Fennec Pharmaceuticals (FRX), Bioventix (BVXP), Redx Pharma (REDX), BriaCell Therapeutics (BCT) and Agronomics (ANIC).
View all of TILS's competitors.
What other stocks do shareholders of Tiziana Life Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Tiziana Life Sciences investors own include Synergy Pharmaceuticals (SGYP), Micron Technology (MU), ServiceNow (NOW), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Broadcom (AVGO), Dropbox (DBX), Enterprise Products Partners (EPD) and Franco-Nevada (FNV).

What is Tiziana Life Sciences' stock symbol?: Tiziana Life Sciences trades on the London Stock Exchange (LON) under the ticker symbol "TILS."
How do I buy shares of Tiziana Life Sciences?: Shares of TILS and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.
How much money does Tiziana Life Sciences make?: Tiziana Life Sciences (LON:TILS) has a market capitalization of £0.00 and generates £-3.60 million in revenue each year.
How many employees does Tiziana Life Sciences have?: Tiziana Life Sciences employs 11 workers across the globe.
How can I contact Tiziana Life Sciences?: Tiziana Life Sciences' mailing address is 3rd Fl, 11-12 St. James's Square, LONDON, SW1Y 4LB, United Kingdom. The official website for Tiziana Life Sciences is www.tizianalifesciences.com. The biotechnology company can be reached via phone at +44-20-74952379.

This page (LON:TILS) was last updated on 6/26/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

MarketBeat Resources